Uncertainties about the benefit-risk balance of oncology medicines assessed by the European Medicines Agency
AC Taams, CA Herberts, ACG Egberts, N Zafiropoulos, F Pignatti, LT Bloem · 2024
Read Uncertainties about the benefit-risk balance of oncology medicines assessed by the European Medicines Agency by AC Taams, CA Herberts, ACG Egberts, N Zafiropoulos, F Pignatti, LT Bloem (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11696770.txt.
Description
Anouk Taams and five co-authors catalogued the open doubts that Europe's drug agency records when it clears new cancer drugs, in a study published in two thousand twenty-four. Every approval weighs gains against risks, and some doubts stay open at the time of the call. The team read agency reports for all new cancer drugs cleared between two thousand eleven and two thousand twenty-two.
One hundred twenty-one drugs carried eight hundred recorded doubts, about six per drug. Half the doubts were about safety and two in five about whether the drug works as hoped. Far fewer touched drug handling, daily use, or product quality. The team sorted the doubts into five groups and twenty-seven subgroups. They offer the scheme as a way to talk plainly about what is not yet known when a drug launches.
Catalog record
| CREATOR | AC Taams, CA Herberts, ACG Egberts, N Zafiropoulos, F Pignatti, LT Bloem |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 100 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |